-
CF Therapy Paves Way for Treating Children Ages 6 to 11 in Europe
Symkevi improved the lung clearance in 6- to 11-year-old children with CF in a Phase 3 trial, which paves the way for its request for approval in Europe. Read more about this here.
What are your thoughts on this news?
Sorry, there were no replies found.
Log in to reply.